Comparative Performance of Aptima BV/CV-TV and Vaginal Real Time Assays for the Molecular Diagnosis of Bacterial Vaginosis and Vaginitis.
- 1Servicio de Microbiología, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
- 2Instituto de Investigación Biosanitaria IBS.GRANADA, 18012 Granada, Spain.
- 3CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Abstract
Background/Objectives: Direct comparisons between commercial molecular platforms for vaginitis diagnosis are scarce. We compared the Aptima BV and CV/TV assays (Hologic) with the Vaginal Real Time kit (Vircell) for bacterial vaginosis (BV), Candida spp. and Trichomonas vaginalis, and explored the association between BV and sexually transmitted infection (STI) co-detection. Methods: In this prospective single-centre study, 350 vaginal swabs submitted for molecular STI screening were tested on both platforms. Discordances were arbitrated with the Allplex™ Vaginitis Screening assay (Seegene) within a composite reference standard (CRS). Agreement was assessed with Cohen's κ and positive/negative percentage agreement (PPA/NPA); performance was calculated against the CRS. Results: Agreement was substantial for BV (κ = 0.676; PPA 94.8%, NPA 79.1%) and almost perfect for Candida spp. (κ = 0.885) and T. vaginalis (κ = 0.920), in line with previous molecular-versus-Nugent comparisons. Vircell classified more samples as BV-positive than Aptima (45.4% vs. 33.1%; p < 0.001); the Aptima BV positivity rate closely matched the 34% reported by Vipond et al. Against the CRS, Aptima showed higher specificity (98.7%) and Vircell higher sensitivity (98.3%). Agreement fell to 75.9% in women aged ≥45 years. BV positivity was associated with STI co-detection, strongest for Chlamydia trachomatis (OR 8.97, 95% CI 3.26-24.71). Conclusions: The two platforms performed equivalently for candidiasis and trichomoniasis but diverged for BV, particularly in older women, reflecting their different classification algorithms rather than analytical quality.
Related
- Evaluation of the Hologic Aptima® Vaginitis and Seegene Allplex™ assays for microbiological diagnosis of bacterial vaginosis and Candida vaginitis in women in France, relative to Nugent score and culture.
- Effectiveness of male partner treatment in reducing recurrence of bacterial vaginosis: a systematic review and meta-analysis
- Large-scale metagenomic characterization of the vaginal microbiome and uropathogens in women with recent bacterial vaginosis and urinary tract infections
- Exploratory pilot study of a spray-type probiotic delivery system for vaginal health in women at risk for bacterial vaginosis
- Effect of pHyph, A novel antibiotic-free treatment, on bacterial vaginosis symptoms and vaginal microbiome composition
BibTeX
@article{alvarez2026comparative,
title = {{Comparative Performance of Aptima BV/CV-TV and Vaginal Real Time Assays for the Molecular Diagnosis of Bacterial Vaginosis and Vaginitis.}},
author = {Laura Gozalo Álvarez and Lucía Pérez Rodríguez and Elvira García-Valdecasas García and Ana Fuentes López and Adolfo de Salazar and Federico García},
journal = {Diagnostics (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/diagnostics16193173},
url = {https://europepmc.org/article/MED/42882328},
note = {CC BY},
}
RIS
TY - JOUR
TI - Comparative Performance of Aptima BV/CV-TV and Vaginal Real Time Assays for the Molecular Diagnosis of Bacterial Vaginosis and Vaginitis.
AU - Laura Gozalo Álvarez
AU - Lucía Pérez Rodríguez
AU - Elvira García-Valdecasas García
AU - Ana Fuentes López
AU - Adolfo de Salazar
AU - Federico García
PY - 2026
DA - 2026/09/29
JO - Diagnostics (Basel, Switzerland)
DO - 10.3390/diagnostics16193173
UR - https://europepmc.org/article/MED/42882328
AB - Background/Objectives: Direct comparisons between commercial molecular platforms for vaginitis diagnosis are scarce. We compared the Aptima BV and CV/TV assays (Hologic) with the Vaginal Real Time kit (Vircell) for bacterial vaginosis (BV), Candida spp. and Trichomonas vaginalis, and explored the association between BV and sexually transmitted infection (STI) co-detection. Methods: In this prospective single-centre study, 350 vaginal swabs submitted for molecular STI screening were tested on both platforms. Discordances were arbitrated with the Allplex™ Vaginitis Screening assay (Seegene) within a composite reference standard (CRS). Agreement was assessed with Cohen's κ and positive/negative percentage agreement (PPA/NPA); performance was calculated against the CRS. Results: Agreement was substantial for BV (κ = 0.676; PPA 94.8%, NPA 79.1%) and almost perfect for Candida spp. (κ = 0.885) and T. vaginalis (κ = 0.920), in line with previous molecular-versus-Nugent comparisons. Vircell classified more samples as BV-positive than Aptima (45.4% vs. 33.1%; p < 0.001); the Aptima BV positivity rate closely matched the 34% reported by Vipond et al. Against the CRS, Aptima showed higher specificity (98.7%) and Vircell higher sensitivity (98.3%). Agreement fell to 75.9% in women aged ≥45 years. BV positivity was associated with STI co-detection, strongest for Chlamydia trachomatis (OR 8.97, 95% CI 3.26-24.71). Conclusions: The two platforms performed equivalently for candidiasis and trichomoniasis but diverged for BV, particularly in older women, reflecting their different classification algorithms rather than analytical quality.
SN - 2075-4418
ER -